Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the
accumulation of beta-amyloid (Aβ) protein and neurofibrillary tangles in the brain, resulting …

Cerebrospinal fluid (CSF) amyloid-β peptide (Aβ) 42/Aβ40 and the concentration of tau
phosphorylated at site 181 (p-tau181) are well-established biomarkers of Alzheimer's …

Objective A clock relating amyloid positron emission tomography (PET) to time was used to
estimate the timing of biomarker changes in sporadic Alzheimer disease (AD). Methods …

Anti-amyloid treatments for early symptomatic Alzheimer disease have recently become
clinically available in some countries, which has greatly increased the need for biomarker …

Background Alzheimer's disease (AD) cerebrospinal fluid (CSF) core biomarkers (Aβ42/40
ratio, p-tau, and t-tau) provide high diagnostic accuracy, even at the earliest stage of …

INTRODUCTION To examine the extent to which positron emission tomography (PET)‐,
cerebrospinal fluid (CSF)‐, and plasma‐related amyloid‐β/tau/neurodegeneration (A/T/N) …

Alzheimer's disease is a progressive neurodegenerative disorder, the early detection of
which is crucial for timely intervention and enrollment in clinical trials. However, the …

There is a growing literature investigating the effects of selenium on the central nervous
system and cognitive function. However, little is known about the role of selenoprotein P, the …

Neuropsychiatric symptoms (NPS), including depression, anxiety, apathy, visual
hallucinations, and impulse control disorders, are very common during the course of …

Alzheimer's disease (AD) is the most common cause of age-associated dementia and will
exponentially rise in prevalence in the coming decades, supporting the parallel …